- American City Business Journals•4 days ago
Drug manufacturer Albany Molecular Research Inc. is looking at a $1 billion sale, according to Bloomberg News. AMRI is working with Credit Suisse Group AG to explore a sale, Bloomberg reports, citing unidentified sources. Carlyle Group LP and Pamplona Capital Management, two private equity firms with records of investing in pharmaceutical and health care deals, have expressed interest.
- PR Newswire•5 days ago
GHP magazine recognizes that the biotechnology industry is increasingly viewed as being the frontline of medical science, and as this movement continues to gain momentum the publication is committed to following the most game-changing advances and revolutionary developments that will form the healthcare world for years to come. Nathan Angell, GHP awards coordinator, expressed pride in every one of the award winners, "This award recognizes the hard work and dedication of the firms, such as SSCI, and the individuals behind them, that are driving innovation in this vital market.
- PR Newswire•6 days ago
ALBANY, N.Y., April 25, 2017 /PRNewswire/ -- AMRI (AMRI) today announced it will issue first quarter 2017 financial results before the opening of the market on Tuesday, May 9, 2017. Following the release of its results, the company will host a conference call and simultaneous audio webcast at 8:30 a.m. ET. The conference call can be accessed by dialing (866) 208-5728 (domestic calls) or (224) 633-1279 (international calls) at 8:20 a.m. ET and entering passcode 7657377. A replay of the conference call can be accessed for 24 hours at (855) 859-2056 (domestic calls) or (404) 537-3406 (international calls) and entering passcode 7657377.
AYM.F : Summary for ALBANY MOLECULAR DL-,01 - Yahoo Finance
Albany Molecular Research, Inc. (AYM.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 4:38PM CEST
|Bid||14.23 x 26300|
|Ask||14.51 x 25300|
|Day's Range||14.81 - 14.93|
|52 Week Range||11.71 - 17.96|
|PE Ratio (TTM)||-8.09|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|